[1]白娟,方红.抗PD-1/PD-L1免疫治疗的皮肤不良反应及其处理[J].中国皮肤性病学杂志,2019,(07):828-831.[doi:10.13735/j.cjdv.1001-7089.201805122]
 BAI Juan,FANG Hong.Dermatologic Adverse Reactions to Anti-PD-1/PD-L1 Immunotherapy and Their Management[J].The Chinese Journal of Dermatovenereology,2019,(07):828-831.[doi:10.13735/j.cjdv.1001-7089.201805122]
点击复制

抗PD-1/PD-L1免疫治疗的皮肤不良反应及其处理
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2019年07期
页码:
828-831
栏目:
综述
出版日期:
2019-06-16

文章信息/Info

Title:
Dermatologic Adverse Reactions to Anti-PD-1/PD-L1 Immunotherapy and Their Management
文章编号:
1001-7089(2019)07-0828-04
作者:
白娟方红
浙江大学医学院附属第一医院,浙江 杭州 310003
Author(s):
BAI JuanFANG Hong
(The First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310003,China)
关键词:
程序性死亡分子1 程序性死亡分子配体1 免疫相关副作用 皮肤
Keywords:
Programmed cell death 1 Programmed death ligand 1 Immune-related adverse event Skin
分类号:
R 457.2; R 751
DOI:
10.13735/j.cjdv.1001-7089.201805122
文献标志码:
A
摘要:
程序性死亡分子1(PD-1)及其配体程序性死亡分子配体1(PD-L1)是第二代免疫检查点抑制剂的临床靶点。FDA已批准上市多种PD-1/PD-L1单抗用于治疗晚期和转移性癌症。皮肤不良反应是最常见的免疫相关副作用之一。临床表现为非特异性皮疹、瘙痒、白癜风、苔藓样皮炎、银屑病、大疱性类天疱疮、结节病、脱发、重症药疹等。早期识别和管理可能有助于获得更精确的诊断和治疗,避免影响肿瘤治疗进程及减少对患者生活质量的负性影响。
Abstract:
Programmed cell death 1(PD-1)and its ligand programmed death ligand 1(PD-L1)are the most crucial targets of next generation immune checkpoint inhibitors.Various PD-1/PD-L1 monoclonal antibodies have been approved by FDA for advanced and metastatic cancers.Dermatologic adverse events(AEs)are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy,including non-specific skin rashes,pruritis,vitiligo,lichen dermatitis,psoriasis,bullous pemphigus,sarcoidosis,alopecia,and severe drug eruption.Early identification and appropriate management are helpful to obtain more accurate diagnosis and treatment,thereby avoiding possible interruption of tumor treatments and reducing the negative impact on patients' quality of life.

参考文献/References:

[1] La Fleur MW,Muroyama Y,Drake CG,et al.Inhibitors of the PD-1 Pathway in tumor therapy[J].J Immunol,2018,200(2):375-383.
[2] Gong J,Chehrazi-Raffle A,Reddi S,et al.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy:a comprehensive review of registration trials and future considerations[J].J Immunother Cancer,2018,6(1):8.
[3] Medina PJ,Adams VR.PD-1 pathway inhibitors:immuno-oncology agents for restoring antitumor immuneresponses[J].Pharmacotherapy,2016,36(3):317-334.
[4] Lee HT,Lee JY,Lim H,et al.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodiesatezolizumab and durvalumab[J].Sci Rep,2017,7(1):5532.
[5] Sibaud V.Dermatologic reactions to immune checkpoint inhibitors:skin toxicities and immunotherapy[J].Am J Clin Dermatol,2018,19(3):345-361.
[6] Weber JS,Hodi FS,Wolchok JD,et al.Safety profile of nivolumab monotherapy:a pooled analysis of patients with advanced melanoma[J].J Clin Oncol,2017,35(7):785-792.
[7] Curry JL,Tetzlaff MT,Nagarajan P,et al.Diverse types of dermatologic toxicities from immune checkpoint blockade therapy[J].J Cutan Pathol,2017,44(2):158-176.
[8] Sibaud V,Meyer N,Lamant L,et al.Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies[J].Curr Opin Oncol,2016,28(4):254-263.
[9] Shao K,Mc Gettigan S,Elenitsas R,et al.Lupus-like cutaneous reaction following pembrolizumab:An immune-related adverse event associated with anti-PD-1 therapy[J].J Cutan Pathol,2018,45(1):74-77.
[10] Larsabal M,Marti A,Jacquemin C,et al.Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo[J].J Am Acad Dermatol,2017,76(5):863-870.
[11] Hua C,Boussemart L,Mateus C,et al.Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab[J].JAMA Dermatol,2016,152(1):45-51.
[12] Hofmann L,Forschner A,Loquai C,et al.Cutaneous,gastrointestinal,hepatic,endocrine,and renal side-effects of anti-PD-1 therapy[J].Eur J Cancer,2016,60:190-209.
[13] Schaberg KB,Novoa RA,Wakelee HA,et al.Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy[J].J Cutan Pathol,2016,43(4):339-346.
[14] Chou S,Hwang SJ,Carlos G,et al.Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1(anti-PD-1)therapy with or without ipilimumab[J].Am J Dermatopathol,2017,39(1):23-27.
[15] Bonigen J,Raynaud-Donzel C,Hureaux J,et al.Anti-PD1-induced psoriasis:a study of 21 patients[J].J Eur Acad Dermatol Venereol,2017,31(5):e254-e257.
[16] Naidoo J,Schindler K,Querfeld C,et al.Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J].Cancer Immunol Res,2016,4(5):383-389.
[17] Lopez AT,Khanna T,Antonov N,et al.A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors[J].Int J Dermatol,2018,57(6):664-669.
[18] Zarbo A,Belum VR,Sibaud V,et al.Immune-related alopecia(areata and universalis)in cancer patients receiving immune checkpoint inhibitors[J].Br J Dermatol,2017,176:1649-1652.
[19] Vigarios E,Epstein JB,Sibaud V.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors[J].Support Care Cancer,2017,25(5):1713-1739.
[20] Lomax AJ,McGuire HM,McNeil C,et al.Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors:Case series and immunophenotypic analysis[J].Int J Rheum Dis,2017,20(9):1277-1285.

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金(81673045)
[作者单位] 浙江大学医学院附属第一医院,浙江 杭州 310003
[通讯作者] 方红,E-mail:fanghongzy@zju.edu.cn
[Corresponding author] FANG Hong,E-mail:fanghongzy@zju.edu.cn
更新日期/Last Update: 2019-06-15